UDA-6
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity.
For research use only. We do not sell to patients.
- Formula: C193H315N51O62
- Molecular Weight:4341.87
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
UDA-6 (30 min) potently and equally activates human AMY3R and human CTR in HEK-293 cells, with EC50 values of 0.8 pM and 0.6 pM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
UDA-6 (10-20 nmol/kg; s.c.; daily; 24 days) induces body weight decrease and improves metabolic and hepatic parameters in male DIO SD rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lean SD Rats (male, 8-10 weeks old)[1]
-
Dosage:1; 3; 10; 30 nmol/kg
-
Administration:s.c.; single dose
-
Result:Produced a dose-dependent reduction in body weight and cumulative food intake over 96 hours.
Caused transient food intake inhibition over 24 hours followed by rebound at 1 nmol/kg.
Induced a >10% decrease in body weight relative to vehicle controls and sustained food intake suppression over 48 hours at 30 nmol/kg.
Showed no signs of discomfort, emesis, or behavioral abnormalities at any dose.
-
Animal Model:DIO SD Rats (male, 600-700 g) maintained on a high fat diet (HFD).[1]
-
Dosage:10 ; 20 nmol/kg
-
Administration:s.c.; daily; 24 days
-
Result:Resulted in a maximum mean body weight decrease of 13.1% from baseline at 20 nmol/kg.
Reduced ad libitum fed blood glucose levels, serum AST, ALT, TG, TC, and fasting blood glucose levels relative to vehicle controls.
Reduced liver weight, hepatic TG, and hepatic TC.
Partially alleviated liver inflammation and lipid deposition via oil red O and H&E staining.
Chemical Information
-
Molecular Weight 4341.87
-
Formula C193H315N51O62
-
Sequence
{Pyr}-Ser-His-Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-cyclo{Lys-(PEG2-Gly-Gly-Ser-Gly-Ser-Gly-γGlu-C20 diacid)-Ser-Ala-Glu-Glu}-His-Lys-Leu-{Aib}-Asp-Tyr-Pro-Arg-Thr-Asp-Val-Gly-Ser-Gly-Ala-Pro-NH2
-
Sequence Shortening
{Pyr}-SHLSTAVLGR-cyclo{K-(PEG2-GGSGSG-γGlu-C20 diacid)-SAEE}-HKL-{Aib}-DYPRTDVGSGAP-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)